Rankings
▼
Calendar
MESO FY 2013 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena
MESO
Mesoblast Limited
$2B
FY 2013 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$29M
-24.8% YoY
Gross Profit
$8M
26.1% margin
Operating Income
-$60M
-208.7% margin
Net Income
-$62M
-214.2% margin
EPS (Diluted)
$-1.10
Cash Flow
Operating Cash Flow
-$54M
Free Cash Flow
-$57M
Stock-Based Comp.
$12M
Balance Sheet
Total Assets
$884M
Total Liabilities
$253M
Stockholders' Equity
$630M
Cash & Equivalents
$8M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$29M
$38M
-24.8%
Gross Profit
$8M
$38M
-80.4%
Operating Income
-$60M
-$49M
-23.3%
Net Income
-$62M
-$71M
+13.3%
← FY 2012
All Quarters
FY 2014 →